English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
GEN 与 Sulfateq BV 公布治疗阿尔茨海默病及其他神经退行性疾病的候选药物 SUL-238 的第一阶段临床试验积极结果
Jul 29, 2025 08:00 HKT
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China
Jul 29, 2025 05:00 HKT
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China
Jul 29, 2025 04:00 HKT
HKTDC boosts Hong Kong's competitive edge in high-value services
Jul 28, 2025 23:30 HKT
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Jul 28, 2025 21:00 HKT
KKR、トプコンに対する公開買付けを開始
Jul 28, 2025 19:30 HKT
Doubleview Gold Corp Initiates Advanced Exploration Program at Red Spring, Bolstering Its Critical Minerals Portfolio
Jul 28, 2025 17:39 HKT
小黃鴨德盈發佈2025年中期業績盈喜 預期收入按年增長不低於三成
Jul 28, 2025 17:06 HKT
小黄鸭德盈发布2025年中期业绩盈喜 预期收入按年增长不低于三成
Jul 28, 2025 17:06 HKT
Quantum Solutions Forms Strategic Alliance with TDX Strategies to Advance Bitcoin Treasury Deployment
Jul 28, 2025 16:23 HKT
Quantum Solutions與TDX Strategies達成戰略合作,進一步深化比特幣儲備部署
Jul 28, 2025 16:23 HKT
Quantum Solutions与TDX Strategies达成战略合作 进一步深化比特币储备部署
Jul 28, 2025 16:23 HKT
“粵港澳大灣區醫療保險發展論壇”在港舉行
Jul 28, 2025 15:48 HKT
From Hong Kong Airport to Hengqin: Chimelong Ferry Sets Sail for a Worry-Free Journey
Jul 28, 2025 14:30 HKT
品创控股授购股权 订首三季完成7,500万港元盈利目标 彰显业绩信心 激励雇员共筑长远发展
Jul 28, 2025 13:38 HKT
From Hong Kong Airport to Hengqin: Chimelong Ferry Sets Sail for a Worry-Free Journey
Jul 28, 2025 13:30 HKT
Intelligent Tech Unlocks the Future - Connecting the World, CITIC Telecom Unveils Future-ready Solutions at WAIC 2025
Jul 28, 2025 12:03 HKT
智啟未來 鏈通全球 中信國際電訊集團亮相2025世界人工智能大會
Jul 28, 2025 12:03 HKT
智启未来 链通全球 中信国际电讯集团亮相2025世界人工智能大会
Jul 28, 2025 12:03 HKT
Honda、軽乗用EV「N-ONE e:」をホームページで先行公開
Jul 28, 2025 11:30 HKT
<< Previous Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: